Exposure to low oxygen may help to ease the symptoms of Parkinson’s disease — but a lot more research is needed to conclusively determine the safety and effectiveness of this strategy for use among people with the neurodegenerative disorder, according to a new report. “From a clinical perspective, hypoxia…
News
The U.S. Food and Drug Administration (FDA) has accepted Supernus Pharmaceuticals‘ new application seeking approval of its apomorphine infusion pump — known as SPN-830 — to treat motor fluctuations in people with Parkinson’s disease. A decision on the company’s request, resubmitted last month in the form…
Being diagnosed with depression or having symptoms of the condition significantly increases the risk for developing Parkinson’s disease, according to a study of nearly 100,000 elderly people in South Korea. The association was the greatest for people with a diagnosis of depression and subjective depressive symptoms. Their risk nearly…
EvokAI Creative Labs’ Movement Disorder Monitor (MDM) Flex Sensor — which uses artificial intelligence (AI) in monitoring abnormal body movements — has received CE Mark approval in Europe for the management of Parkinson’s disease and other movement disorders. CE Mark approval indicates that the sensor has been assessed…
Exposure to an air pollutant called fine particular matter (PM2.5) is significantly associated with an increased risk of developing Parkinson’s disease, according to a U.S. population study. “Using state-of-the-art geospatial analytical techniques, we were, for the first time, able to confirm a strong nationwide association between incident Parkinson’s disease…
Engaging in regular physical activity before and after being diagnosed with depression can lower a person’s risk of developing Parkinson’s disease, while stopping to exercise increases that risk, a large study that followed patients in South Korea for about five years reports. Becoming more active only after a depressive…
Enrollment is now complete for a Phase 2 trial that’s assessing the safety and efficacy of oral vodobatinib (K0706), an experimental Abl inhibitor, in people with early Parkinson’s disease across 84 clinical sites in the U.S., Europe, and India. The placebo-controlled trial (NCT03655236), dubbed PROSEEK and sponsored by Sun…
A trial investigating the feasibility and impact of a novel approach for increasing regular exercise among Hispanic people with Parkinson’s disease — the ethnic group in the U.S. with the highest incidence of the neurodegenerative condition — is now recruiting participants. The aim of the new approach is boosting…
Opal, Clario’s wearable sensor device, was shown to detect early motor progression in people with Parkinson’s disease more rapidly than did standard clinical rating scales. These findings suggest that this new wearable technology may work better than conventional tests to identify patients with worsening motor symptoms. Such a…
ABBV-951 (foslevodopa/foscarbidopa) — Abbvie’s continuous infusion formulation of levodopa/carbidopa that’s administered under the skin — will now be accessible at low or no cost to people in England with advanced Parkinson’s disease whose severe motor fluctuations are no longer controlled by standard treatments. That’s according to the…
Recent Posts
- When love can’t put things back on track, it finds a new way to keep going
- Large study: Quitting smoking linked to increased risk of Parkinson’s
- A vocabulary lesson Parkinson’s families will intimately understand
- States push to ban or restrict paraquat, a herbicide linked to Parkinson’s
- My experiences with the stages of grief since my Parkinson’s diagnosis